More debate about whether the lowest-risk prostate cancers should even be called "cancer." (Harvard Health Publishing) Four cancer drugs -- palbociclib (Ibrance), enzalutamide (Xtandi), pomalidomide ...

The NCCN's new resource educates patients on genetic testing for hereditary cancer risk, focusing on breast, ovarian, pancreatic, and prostate cancers. Advances in genetic technology, spurred by ...